# Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect

> **NCT02268760** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 103 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BILN 2061 ZW single rising doses
- **DRUG:** Placebo
- **DRUG:** BILN 2061 ZW fixed dose
- **OTHER:** Standardized breakfast

## Key facts

- **NCT ID:** NCT02268760
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2001-09
- **Final completion:** —
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268760, "Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02268760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*